The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Pancreatic Ductal Adenocarcinoma (Detailed)

Aggressive epithelial tumor of the pancreatic duct with a poor overall prognosis.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Pancreatic Ductal Adenocarcinoma (Detailed)?

Pancreatic ductal adenocarcinoma arises from the exocrine pancreatic duct epithelium and accounts for over 90% of pancreatic malignancies. Annual incidence in industrialized countries is 8-12 per 100,000, with peak diagnosis between 65-75 years. Despite advances, the 5-year overall survival remains under 12% because most patients present with locally advanced or metastatic disease.

KRAS mutation drives more than 90% of cases, complemented by inactivation of TP53, CDKN2A, and SMAD4. Molecular subtypes (classical and basal-like) are emerging therapeutic biomarkers. Germline BRCA1/2, PALB2, ATM, and Lynch syndrome account for 5-10% of cases and may benefit from targeted PARP inhibitors or immunotherapy.

Surgical resection (Whipple, distal, or total pancreatectomy) is the only curative option, suitable for fewer than 20% of patients. Borderline-resectable and locally advanced disease is now treated with neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) followed by re-evaluation. Metastatic disease relies on first-line FOLFIRINOX or gemcitabine/nab-paclitaxel and second-line liposomal irinotecan or 5-FU regimens. Multidisciplinary care including supportive nutrition is essential.

Symptoms

Painless or progressive jaundice (often head of pancreas)
Epigastric pain radiating to the back
Unexplained weight loss
New-onset or worsening diabetes after age 50
Anorexia, early satiety
Steatorrhea (pale, fatty stools)
Pruritus from cholestasis
Fatigue, weakness, and depression

Risk Factors

Cigarette smoking (doubles risk)
Type 2 diabetes mellitus
Chronic pancreatitis (especially hereditary)
Obesity and metabolic syndrome
Family history (BRCA1/2, PALB2, ATM, Lynch, FAMMM)
Older age (peak 65-75 years)
Heavy alcohol consumption
Occupational exposure to chemicals (chlorinated hydrocarbons, pesticides)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Painless jaundice with weight loss
  • Persistent epigastric pain radiating to the back
  • New diabetes after age 50
  • Unexplained, ongoing weight loss
  • Steatorrhea with malabsorption
  • Family history with concerning symptoms

Treatment Methods

01
Surgery: pancreaticoduodenectomy (Whipple), distal pancreatectomy, or total pancreatectomy when feasible
02
Adjuvant chemotherapy: modified FOLFIRINOX (preferred) or gemcitabine-based
03
Neoadjuvant therapy: borderline-resectable and locally advanced cases
04
Metastatic first-line: FOLFIRINOX or gemcitabine plus nab-paclitaxel
05
Targeted therapy: PARP inhibitors (olaparib) for BRCA1/2; pembrolizumab for MSI-high tumors; KRAS G12C inhibitors for select patients
06
Symptom control: biliary stenting, celiac plexus block, pancreatic enzyme replacement
07
Nutritional and psychosocial support, palliative care integration
08
Genetic counseling and screening for high-risk family members

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.